Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology Annual Meeting.

13 Dec 2022

Simplified treatment regimen results in dramatic decrease in early deaths from acute promyelocytic leukemia

The use of a simplified treatment regimen by oncologists, along with management recommendations and 24/7 support provided by a limited and dedicated group of academic disease experts, resulted in a dramatic decrease in early deaths from acute promyelocytic leukemia (APL).

12 Dec 2022

Pediatric acute myeloid leukemia genetic subtypes with poor outcomes show increased inflammatory cytokine signaling

Researchers used ribonucleic acid (RNA) sequence data to understand the association between inflammatory cytokines and poor outcomes of pediatric Acute Myeloid Leukemia (pAML).

29 Nov 2022

Research findings could bolster the effectiveness of immune-checkpoint therapy

Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system's T cells to attack tumor cells.

16 Nov 2022

Automated Zebrafish screening for Myeloid Leukemia drug discovery

In this interview, NewsMedical speaks to Elspeth Payne and Alexandra Lubin at IDEA Bio-medical, who explain how they use zebrafish modeling to study the development of myeloid leukemias.

From IDEA Bio-Medical Ltd. 15 Nov 2022

New review elucidates current treatment approaches for myelodysplastic syndromes

Physician scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have published a review in the Journal of the American Medical Association that clarifies current treatment approaches for myelodysplastic syndromes (MDS), which are rare and often deadly bone marrow cancers.

1 Nov 2022

Researchers set sights on a new therapeutic target for aggressive breast cancer

Researchers at VCU Massey Cancer Center have set their sights on a new therapeutic target for an aggressive form of breast cancer with limited treatment options.

25 Oct 2022

Researchers discover how cancer cells can turn off the immune system to help tumors grow

When cancer arises in the body, it starts with tumor cells that rapidly grow and divide and eventually spread.

29 Sep 2022

St. Baldrick's Scholar grant awarded to CU researcher for investigating new drug to treat infant leukemia

As part of its ongoing efforts to eradicate childhood cancers, the St. Baldrick's Foundation has awarded University of Colorado Cancer Center member Kelly Faulk, MD, a St. Baldrick's Scholar grant to investigate a new method for treating infant leukemia.

9 Sep 2022

Researchers discover a new class of more potent and less toxic drugs for leukemia patients

Chemotherapy sucks. The treatments generally have awful side effects, and it's no secret that the drugs involved are often toxic to the patient as well as their cancer.

24 Aug 2022

Smoking continues to be a leading cause of cancer-related death

A new study led by researchers at the American Cancer Society (ACS) reports nearly 123,000 cancer deaths, or close to 30 percent of all cancer deaths, were from cigarette smoking in the United States in 2019, leading to more than two million Person-Years of Lost Life (PYLL) and nearly $21 billion in annual lost earnings. These losses were disproportionately higher in states with weaker tobacco control policies in the South and Midwest. The results were published today in the International Journal of Cancer.

11 Aug 2022

Study reveals a specific metabolic adaptation in some patients with acute myeloid leukemia

An article published in the journal Nature Communications describes a specific metabolic adaptation in some patients with acute myeloid leukemia affected by tandem mutations in the FLT3 gene.

13 Jul 2022

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

6 Jul 2022

Researchers develop new chemistry on natural compounds to obtain a therapeutic agent for treating leukemia

Natural compounds often have promising therapeutic potential but their use to treat diseases is hampered due to toxicity or non-desirable effects.

27 Jun 2022

Promising results of combination treatment for acute myeloid leukemia to be presented at ASCO 2022

On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).

6 Jun 2022

Three-drug therapy with autologous stem cell transplant improves progression-free survival for multiple myeloma patients

Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.

6 Jun 2022

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.

2 Jun 2022

Risk factors for COVID-19 in patients with hematological malignancies

Researchers investigate the risk factors present in individuals suffering from hematological malignancies and COVID-19.

26 May 2022

Adolescent and young adult leukemia survivors have reduced long-term survival compared to peers without cancer

Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult (AYA) cancer survivors of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) have reduced long-term survival rates compared to their peers without cancer.

13 May 2022

Researchers make breakthrough in overcoming drug resistance in a rare, devastating blood cancer

South Australian scientists have made a significant breakthrough in overcoming drug resistance in acute myeloid leukemia (AML), a rare and devastating blood cancer that kills most patients within a few years.

9 May 2022